View Cart (0 items)
Pharmaceutical

ASLAN Pharmaceuticals, Bristol-Myers Squibb partner to develop cancer treatment

November 03, 2011
/ Print / Reprints /
| Share More
/ Text Size+

SINGAPORE and PRINCETON, N.J. — Singapore-based ASLAN Pharmaceuticals and Bristol-Myers Squibb today announced a strategic partnership allowing for the rapid development of BMS-777607, Bristol-Myers Squibb''s investigational small molecule inhibitor of the MET receptor tyrosine kinase for treatment of solid tumors, according to a press release.

Under the terms of the agreement, ASLAN will receive exclusive rights to develop and commercialize BMS-777607 in China, Australia, Korea, Taiwan and other selected Asian countries while Bristol-Myers Squibb retains exclusive rights in the rest of the world.

"This ground-breaking partnership demonstrates how a leading Asian drug development company can work together with a global biopharmaceutical company to accelerate drug development and conduct early clinical studies in Asia in areas of significant unmet need," said Dr. Carl Firth, CEO of ASLAN.
You must login or register in order to post a comment.